Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

Neoadjuvant osimertinib with or without chemotherapy demonstrated statistically significant improvement in the MPR rate over chemotherapy alone in patients with resectable, <i>EGFR</i>-mutated, stage II-IIIB NSCLC.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-06-02
DOI
https://doi.org/10.1200/jco-25-00883
Citations
40
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
60.73
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer

Yasuhiro Tsutani, Ligang Xing, David J. Finley, Jair Bar et al.
40 citations
Journal of Clinical Oncology
Lung Cancer Treatments and Mutations
60.73
article

Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer

Yasuhiro Tsutani, Ligang Xing, David J. Finley, Jair Bar, Julia Rotow, Mustafa Dikilitaş, Bentong Yu, Alex Martínez‐Martí, Collin M. Blakely, Justyna Rawluk, Maximilian J. Hochmair, Akira Ono, Shuji Murakami, Noriko Yanagitani, Toshi Menju, Prabhat Singh Malik, Yuri Rukazenkov, Chao-Hsun Chen, Elizabeth Dudnik, Gaofeng Li, Buhai Wang, Hidemi Suzuki, Erminia Massarelli, Yuh‐Min Chen, Dat T. Vo, Froylán López-López, W. Weder, Seung Soo Yoo, Piyada Sitthideatphaiboon, Somcharoen Saeteng, Hiroshi Tanaka, Sun Hyo Park, Miyako Satouchi, Óscar Arrieta, Ming‐Hsun Wu, Jonathan Wade Goldman, P. K. Yаblonskiy, José Fernando Bastos de Moura, Velko Minchev, Jusang Kim, Hien P. Nguyen, Alexander I. Spira, Ulrich Richter, Masahiro Tsuboi, Maria Paz Saavedra, Jin‐Yuan Shih, Wentao Fang, Jonathan Spicer, Marc de Perrot, Clarissa Baldotto, Mehmet Alı Nahıt Şendur, Adam J. Bograd, Diego Cortinovis, Carles Escriu, Guzel Mukhametshina, Ian C. Anderson, Ming Zhou, Jiro Okami, Marcelo Garrido, Seung Hyeun Lee, Maira Elizabeth Moreno Saavedra, Jarosław Kołb-Sielecki, R. Krasteva, Sung Yong Lee, Yasushi Yatabe, Bhavesh Poladia, Arya Amini, Gudrun Absenger, Qixun Chen, Jingdi Wang, Walter Weder, Catherine A. Shu, Kang‐Yun Lee, Kaican Cai, Lunxu Liu, Shunichi Sugawara, Touch Ativitavas, Seong Hoon Yoon, Chao Cheng, Hataiwan Ratanabunjerdkul, Mariano Provencio, Kazuya Takamochi, Nataliya Chilingirova, Jamie E. Chaft, S. Galland-Girodet, Manoch Buranachokphaisan, Qun Wang, Chang Chen, Nan Wu, Wenxiang Wang, Jun Zhao, Shanqing Li, Jianxing He, Quan Lin, Runxiang Yang, Sabrina Rossi, Nguyen Viet Nhung, Lunxu Liu, Jarin Chindaprasirt, Ke‐Neng Chen, Shobhit Baijal, Mai Thi Chi Tran, Vinh Vu, M. Dómine Gómez, Domenico Galetta, Norihiko Ikeda, Kang-Yun Lee, Morihito Okada, Han-Pin Kuo, Wolfgang Schütte, Anupriya Dayal, Silvia Novello, Xiangning Huang, Jerónimo Rodríguez Cid, Carlos Henrique Andrade Teixeira, Frank Griesinger, Sanja Dacic, Yong Han, Gee Chen Chang, José Elias Miziara, Georgia Fiuza Alencar Araripe, Nguyen Hoang Gia, Wei Dong Zhang, Tatiana Kleimenteva, Collin M. Blakley, Duan Hongbing
article en
40 citations

Abstract

Neoadjuvant osimertinib with or without chemotherapy demonstrated statistically significant improvement in the MPR rate over chemotherapy alone in patients with resectable, <i>EGFR</i>-mutated, stage II-IIIB NSCLC.

Journal of Clinical OncologyVol. 43(26)
AstraZeneca (United Kingdom) (GB), Memorial Sloan Kettering Cancer Center (US), University of Liverpool (GB), Vietnam National University, Hanoi (VN), University of California, San Francisco (US), Peking University (CN), University of Zurich (CH), Cornell University (US), Sichuan University (CN), Korea University Medical Center (KR), Clatterbridge Cancer Centre NHS Foundation Trust (GB), Kanagawa Prefectural Hospital Organization (JP), Yale University (US), West China Hospital of Sichuan University (CN), Peking University Cancer Hospital (CN), Hospital Alemão Oswaldo Cruz (BR), First Affiliated Hospital of Guangzhou Medical University (CN), Shandong Tumor Hospital (CN), AstraZeneca (Netherlands) (NL), AstraZeneca (Singapore) (SG), Sichuan Cancer Hospital (CN), Vall d'Hebron Hospital Universitari (ES), National Taiwan University Hospital (TW), AstraZeneca (Poland) (PL), National Cancer Center Hospital East (JP), Ministry of Education (ET), Pusan National University Yangsan Hospital (KR), AstraZeneca (Spain) (ES), State Key Laboratory of Respiratory Disease (CN), Taipei Medical University-Shuang Ho Hospital (TW), Hanoi Lung Hospital (VN), Karl Landsteiner Society (AT), Shandong First Medical University (CN), UCSF Helen Diller Family Comprehensive Cancer Center (US), Vall d'Hebron Institute of Oncology (ES), Chiang Mai University (TH), Guangzhou Medical University (CN)
Good health and well-being
Openalex Percentile: Top 0%
Lung Cancer Treatments and Mutations
60.73
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.